Janux Therapeutics
JANX · Nasdaq · United States
Share price · JANX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when JANX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-27.6%
- 6 Nov 2026+9.8%
- 7 Oct 2026+6.7%
Nothing announced by JANX that day or the session before.
- 10 Sep 2026-8.5%
Nothing announced by JANX that day or the session before.
- 24 Aug 2026+7.0%
Nothing announced by JANX that day or the session before.
- 18 Aug 2026+4.3%
Nothing announced by JANX that day or the session before.
- 8 Jul 2026+3.2%
Nothing announced by JANX that day or the session before.
- 1 Jul 2026-4.6%
Nothing announced by JANX that day or the session before.
- 2 Dec 2025-53.3%
Nothing announced by JANX that day or the session before.
- 25 Nov 2025+10.2%
Nothing announced by JANX that day or the session before.
Share of unusual movement by asset
For each asset, the share of JANX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
JANX007events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 24% |
| Other company news (earnings, financing, releases naming no asset) | — | 13% |
| Sessions with no dated event | — | 63% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | PSMA x CD3Multispecific antibody | Prostate Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $9.3M | $31M | $42M+ $904M short-term inv. | $22M-$25M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $10M | $31M | $28M+ $943M short-term inv. | $22M$12M operating cash flow | report ↗ |
| 2026-Q1 | $3.7M | $27M | $52M+ $905M short-term inv. | $24M-$12M operating cash flow | report ↗ |
| 2025-Q3 | $10M | $35M | $48M+ $941M short-term inv. | $24M-$13M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $35M | $52M+ $944M short-term inv. | $34M-$24M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $25M | $74M+ $940M short-term inv. | $24M-$17M operating cash flow | report ↗ |
| 2024-Q3 | $0.4M | $19M | $27M+ $631M short-term inv. | $28M-$2.2M operating cash flow | report ↗ |
| 2024-Q2 | $8.9M | $15M | $15M+ $632M short-term inv. | $6.0M-$10M operating cash flow | report ↗ |
| 2024-Q1 | $1.3M | $14M | $213M+ $439M short-term inv. | $15M-$15M operating cash flow | report ↗ |
| 2023-Q3 | $2.5M | $12M | $17M+ $333M short-term inv. | $12M-$12M operating cash flow | report ↗ |
| 2023-Q2 | $1.1M | $15M | $34M+ $270M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2023-Q1 | $2.0M | $16M | $30M+ $287M short-term inv. | $17M-$14M operating cash flow | report ↗ |
| 2022-Q3 | $1.8M | $14M | $65M+ $274M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2022-Q2 | $2.4M | $14M | $58M+ $296M short-term inv. | $17M-$6.1M operating cash flow | report ↗ |
| 2022-Q1 | $1.6M | $10M | $55M+ $306M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2021-Q3 | $1.2M | $8.4M | $39M+ $348M short-term inv. | $11M-$5.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $10M | $126M | $52M+ $914M short-term inv. | $28M-$82M operating cash flow | report ↗ |
Janux Therapeutics reported 2025 collaboration revenue of $10.0M, down 5.6% YoY from $10.59M, and R&D expenses of $125.9M, up 84.1% YoY from $68.39M. Cash and equivalents were $52.33M at year-end, with short-term investments of $914.23M and total cash, equivalents and short-term investments of $966.6M. The company reported a full-year net loss of $113.62M and a quarterly net burn of $113.63M.
Janux presented updated interim Phase 1 data for JANX007 in December 2025, covering 109 patients as of the October 15, 2025 cutoff, with median radiographic progression-free survival of 7.9 to 8.9 months and confirmed or unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients; JANX007 is enrolling a Phase 1b taxane-naïve mCRPC population, JANX008 is enrolling expansion cohorts in defined solid tumors, and JANX011 has initiated a Phase 1 healthy-volunteer study. In January 2026, Janux entered a collaboration and exclusive worldwide license with Bristol Myers Squibb for a novel tumor-activated therapeutic, with $50M in upfront and near-term milestone payments, potential milestones of approximately $800M, and tiered royalties. William Go, M.D., Ph.D. was appointed Chief Medical Officer, and the company expects additional JANX007 data in 2026, a JANX008 clinical update in 2026, and an initial JANX011 update by year-end 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $11M | $68M | $431M+ $595M short-term inv. | $17M-$44M operating cash flow | report ↗ |
| 2023-FY | $8.1M | $55M | $19M+ $325M short-term inv. | $15M-$51M operating cash flow | report ↗ |
| 2022-FY | $8.6M | $53M | $51M+ $276M short-term inv. | $16M-$43M operating cash flow | report ↗ |
| 2021-FY | $3.6M | $26M | $36M+ $339M short-term inv. | $8.2M-$17M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($457K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan · director, President and CEO | Gift | 123,840 | — | — | Form 4 |
| 2026-07-08 | Campbell David Alan · director, President and CEO | Option exercise | 7,000 | $4.21 | $29K | Form 4 |
| 2026-07-08 | Campbell David Alan · director, President and CEO | Option exercise (derivative) | 7,000 | — | — | Form 4 |
| 2026-06-11 | Barrett Ronald W · director | Award / grant | 5,500 | — | — | Form 4 |
| 2026-06-11 | CAPPS VICKIE L · director | Award / grant | 5,500 | — | — | Form 4 |
| 2026-06-11 | DOBMEIER ERIC · director | Award / grant | 5,500 | — | — | Form 4 |
| 2026-06-11 | Hernday Natasha · director | Award / grant | 5,500 | — | — | Form 4 |
| 2026-06-11 | Kung Winston · director | Award / grant | 5,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 189 reporting institutions held 59.6M shares ($812.2M, 97.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11,189,693 | $155.5M |
| 2 | BlackRock, Inc. | 5,433,233 | $75.5M |
| 3 | JANUS HENDERSON GROUP PLC | 4,196,409 | $58.3M |
| 4 | Prosight Management, LP | 3,550,000 | $49.3M |
| 5 | FMR LLC | 2,535,724 | $35.2M |
| 6 | STATE STREET CORP | 2,464,017 | $34.2M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,811,365 | $25.2M |
| 8 | TCG Crossover Management, LLC | 1,789,617 | $24.9M |
| 9 | Alyeska Investment Group, L.P. | 1,601,089 | $22.3M |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 1,597,650 | $22.2M |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,290,256 | $17.9M |
| 12 | Deep Track Capital, LP | 1,187,290 | $16.5M |
| 13 | Point72 Asset Management, L.P. | 1,156,140 | $16.1M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1,146,724 | $15.9M |
| 15 | Balyasny Asset Management L.P. | 1,090,147 | $15.2M |